Diagnostic Kits/Bibliography by Research Question: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
(New page: Bibliographic entries used in each research question (1-12; defined by the Field Research Methodology). = Overview of Economics of Intellectual Property in Kits = = Give an overall p...)
 
 
(24 intermediate revisions by 2 users not shown)
Line 2: Line 2:


= Overview of Economics of Intellectual Property in Kits =
= Overview of Economics of Intellectual Property in Kits =
* Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing: A Roadmap to Diagnostics in the 21st Century - market research report. Available at: http://www.reportlinker.com/p091997/Diagnostic-Test-Service-Commercialization-in-Multiplex-and-Esoteric-Testing-A-Roadmap-to-Diagnostics-in-the-21st-Century.html?utm_source=LivePR&utm_medium=pr&utm_campaign=LivePR [Accessed August 6, 2009].
**[[Diagnostic_Kits/Diagnostic Test Service Commercialization in Multiplex and Esoteric Testing|Highlights]]
* Esther van Zimmeren et al. 2006.Bulletin of the World Health Organization - A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions? Available at: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862006000500013 [Accessed August 10, 2009].
**[[Diagnostic_Kits/A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions|Highlights]]
* Jensen, K. & Murray, F., 2005. INTELLECTUAL PROPERTY: Enhanced: Intellectual Property Landscape of the Human Genome. Science, 310(5746), 239-240.
**[[Diagnostic_Kits/Intellectual Property Landscape of the Human Genome|Highlights]]
* Merz, J.F., 1999. Disease Gene Patents: Overcoming Unethical Constraints on Clinical Laboratory Medicine. Clin Chem, 45(3), 324-330.(Merz 1999) Available at: http://www.clinchem.org/cgi/content/abstract/45/3/324 [Accessed August 5, 2009].
**[[Diagnostic_Kits/Disease Gene Patents|Highlights]]
* Mills, A.E. & Tereskerz, P., 2008. DNA-based patents: an empirical analysis. Nat Biotech, 26(9), 993-995.
**[[Diagnostic_Kits/DNA-based patents: an empirical analysis|Highlights]]
* Pressman, L. et al., 2006. The licensing of DNA patents by US academic institutions: an empirical survey. Nat Biotech, 24(1), 31-39
**[[Diagnostic_Kits/The licensing of DNA patents by US academic institutions|Highlights]]
* Verbeure, B., Matthijs, G. & Van Overwalle, G., 2005. Analysing DNA patents in relation with diagnostic genetic testing. Eur J Hum Genet, 14(1), 26-33. Available at: http://www.nature.com/ejhg/journal/v14/n1/full/5201503a.html [Accessed August 11, 2009].
**[[Diagnostic_Kits/Analysing DNA patents in relation with diagnostic genetic testing|Highlights]]


= Give an overall picture of the Kits' sector =
= Give an overall picture of the Kits' sector =
*Council of Advisors on Science and Technology (PCAST), ''Priorities for Personalized Medicine'', September 2008 Available at: http://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf
**[[Diagnostic_Kits/Priorities for Personalized Medicine|Highlights]]
*Goodman et al. ''The Value of Diagnostics: Innovation, Adoption and Diffusion Into Health Care''.  (2005) pp. 44-71.  Available at: http://www.advamed.org/MemberPortal/About/Resources/
** [[Diagnostic_Kits/The Value of Diagnostics: Innovation, Adoption and Diffusion Into Health Care|Highlights]]
*Lei et al. ''Patents versus patenting: implications of intellectual property protection for biological research''. Nature Biotechnology (2009) vol. 27 (1) pp. 36-40.  Available at: http://www.nature.com/nbt/journal/v27/n1/full/nbt0109-36.html
** [[Diagnostic_Kits/Patents versus patenting: implications of intellectual property protection for biological research|Highlights]]
*Ouellette, L.L., ''Access to Bio-Knowledge: From Gene Patents to Biomedical Materials''. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1431580 [Accessed October 29, 2009].
*'''*Secretary’s Advisory Committee on Genetics, Health, and Society, ''U.S. System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human Services'', April 2008. Available at: http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_oversight_report.pdf [Accessed July 8, 2009].'''
**[[Diagnostic_Kits/SACGHS_U.S. System of Oversight of Genetic Testing|Highlights]]


= Outputs and Products of the field: data, narratives and tools produced by the Kits' sector =
= Outputs and Products of the field: data, narratives and tools produced by the Kits' sector =
*Secretary's Advisory Committee on Genetics, Health, and Society ''€”Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests - Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing.''  (2009) Available at: http://oba.od.nih.gov/SACGHS/sacghs_documents.html#GHSDOC_011.
** [[SACGHS Appendix 1- Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing|highlights]]


= Legal tools available for and in use by the actors of Kits' sector: IP in Kits =
= Legal tools available for and in use by the actors of Kits' sector: IP in Kits =
* [http://www.cafc.uscourts.gov/opinions/08-1248ebo.pdf Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co.] 560 F.3d 1366 C.A.Fed. (Mass., 2009)
* [http://www.cafc.uscourts.gov/opinions/06-1634.pdf Classen Immunotherapies, Inc. v. Biogen IDEC], 304 Fed. Appx. 866 (Fed. Cir. 2008)
* Correspondence and Submissions Relating to CellPro March-In Petition. (2008, April 3). Retrieved April 17, 2010, from http://www.nih.gov/icd/od/foia/cellpro/index.htm
* [http://www.patentlyo.com/08-964-chakrabarty.pdf Diamond v. Chakrabarty], 447 U.S. 303 (1980)
*Geertrui Van Overwalle et al., 2005. ''Models for facilitating access to patents on genetic inventions''. Available at: http://www.nature.com/nrg/journal/v7/n2/full/nrg1765.html [Accessed August 10, 2009].
**[[Diagnostic_Kits/Models for facilitating access to patents on genetic inventions|Highlights]]
* [http://supreme.justia.com/us/333/127/case.html Funk Brothers v. Kalo], 333 U.S. 127 (1948) ... 10-11, 15
* [http://supreme.justia.com/us/333/127/case.html Gottschalk v. Benson], 409 U.S. 63 (1972) ... 9
* Holman, Christopher M., The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation. UMKC Law Review, Vol. 76, p. 295, 2007. Available at SSRN: http://ssrn.com/abstract=1090562
* Holman, Christopher. 2008 (Nov 4). "Applying Bilski to Biotechnology and the Life Sciences." ''Patently-O.'' http://www.patentlyo.com/patent/2008/11/applying-bilski.html.
*J.D, M.A.H.P. & Munzer, S.R., Intellectual Property Rights in Genes and Gene Fragments: A Registration Solution for Expressed Sequence Tags. SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=241236 [Accessed October 30, 2009].
* Howlett, M.J. & Christie, A.F., An Analysis of the Approach of the European, Japanese and United States Patent Offices to Patenting Partial DNA Sequences (ESTs). SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=573184 [Accessed October 30, 2009].
* [http://www.cafc.uscourts.gov/opinions/07-1130.pdf In re Bilski], 545 F.3d 943 (C.A.Fed., 2008.).
* [http://www.uspto.gov/web/offices/com/sol/%C3%A2%C2%80%C2%8Bfedcirdecision/%C3%A2%C2%80%C2%8B04-1465.pdf  In re Fisher], 421 F.3d 1365, 1371 (Fed.Cir. 2005).
* Microbiological Research Corp. v. Muna, 625 P.2d 690, 700 (Utah 1981)
* Mueller, J.M., Public Access Versus Proprietary Rights in Genomic Information: What Is the Proper Role of Intellectual Property Rights? SSRN eLibrary. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1367849 [Accessed October 30, 2009].
* Noonan, Kevin.  2009 (Feb 5). "Applying In re Bilski to Diagnostic Method Claims." ''Patent Docs''.  http://www.patentdocs.org/2009/02/applying-in-re-bilski-to-diagnostic-method-claims.html
* Noonan, Kevin.  2009 (Sept 16). "Prometheus Laboratories, Inc. v. Mayo Collaborative Services (Fed. Cir. 2009)." ''Patent Docs''. http://www.patentdocs.org/2009/09/prometheus-laboratories-inc-v-mayo-collaborative-services-fed-cir-2009.html
* [http://faculty.law.pitt.edu/madison/patent/supplement/oreilly_v_morse.html O'Reilly v. Morse], 56 U.S. 62 (1853)
* Pressman, L. et al., 2006. ''The licensing of DNA patents by US academic institutions: an empirical survey''. Nat Biotech, 24(1), 31-39
**[[Diagnostic_Kits/The licensing of DNA patents by US academic institutions|Highlights]]
* [http://www.cafc.uscourts.gov/opinions/08-1403.pdf Prometheus Laboratories, Inc. v. Mayo Collaborative Services]. 2009 WL 2950232 C.A.Fed. (Cal.,2009).
*Verbeure, B. et al., 2006. ''Patent pools and diagnostic testing. Trends in Biotechnology'', 24(3), 115-120.(Verbeure et al. 2006) Available at: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TCW-4J4HK5P-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=8c0fd5a6f1431a3cbfc9ff2f37470c3b [Accessed August 8, 2009].
**[[Diagnostic_Kits/Patent pools and diagnostic testing|Highlights]]
*Esther van Zimmeren et al. 2006. ''Bulletin of the World Health Organization - A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions?'' Available at: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862006000500013 [Accessed August 10, 2009].
**[[Diagnostic_Kits/A clearing house for diagnostic testing: the solution to ensure access to and use of patented genetic inventions|Highlights]]
= Competitive advantages in Kits =
*Caulfield, Timothy, 2009. ''Do Gene Patents Hurt Research?'' Available at: http://www.scienceprogress.org/2009/10/do-gene-patents-hurt-research/comment-page-1/#comment-6370
*Cook-Deegan, R., Chandrasekharan, S. & Angrist, M., 2009. ''The dangers of diagnostic monopolies''. Nature, 458(7237), 405-406.
**[[Diagnostic_Kits/The dangers of diagnostic monopolies|Highlights]]


= Competitive advantages in Kits =  
*Gibson, Johanna, The Discovery of Invention: Gene Patents and the Question of Patentability (January 01, 2007). Journal of Intellectual Property Rights, Vol. 12, No. 1, 2007. Available at SSRN: http://ssrn.com/abstract=1347087
 
*Kane, Eileen, Molecules and Conflict: Cancer, Patents, and Women's Health. American University Journal of Gender, Social Policy & the Law, Vol. 15, No. 2, 2007. Available at SSRN: http://ssrn.com/abstract=960772
 
*Ouellette, Lisa Larrimore, Access to Bio-Knowledge: From Gene Patents to Biomedical Materials (June 25, 2009). Stanford Technology Law Review, N1, 2010. Available at SSRN: http://ssrn.com/abstract=1431580
 
*Paradise, Jordan K., European Opposition to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implications for United States Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA Patent Controversy. Food & Drug Law Journal, Vol. 59, No. 1, 2004. Available at SSRN: http://ssrn.com/abstract=897507


= IP Profile of Biggest for-profit companies in Kits =
= IP Profile of Biggest for-profit companies in Kits =
*Component Database, Available at: http://www.medibix.com/CompanySearch.jsp?cs_choice=c&clt_choice=t&treepath=16842&stype=i [last accessed April 17, 2010]
*DNA testing providers, Available at: http://dnatestindex.com/providers/ [last accessed April 17, 2010]
* Pressman, L., Rohrbaugh, M., and Stephen Finley. "Preliminary Findings from a Population Level Study of DNA Patents."  ''SACGHS Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests''.  (2009) pp. 1-11


= IP Profile of non-profit companies in Kits =
= IP Profile of non-profit companies in Kits =


= IP Profile of Universities working in Kits =  
*Coriell Personal Medicine Collaborative, Available at: cpmc.coriell.org [last accessed April 17, 2010].
 
*Diagnostics for All, Available at: http://www.dfa.org/ [last accessed April 17, 2010] (Whitesides paper microfluidics - based diagnostics; tests non-DNA biomarkers).
 
*Personal Genome Project at Harvard Available at: http://www.personalgenomes.org/ [last accessed April 17, 2010].
 
= IP Profile of Universities working in Kits =
 
*Henry, M.R., Cho, M.K., Weaver, M.A., Merz, J.F. ''A pilot survey on the licensing of DNA inventions''. J. Law Med. Ethics, 31:442-449, 2003 Available at: http://www.bioethics.upenn.edu:16080/prog/ethicsgenes/ [Accessed September 10, 2009].
**[[Diagnostic_Kits/A pilot survey on the licensing of DNA inventions|Highlights]]
 
*Pressman, L. et al., 2006. ''The licensing of DNA patents by US academic institutions: an empirical survey''. Nat Biotech, 24(1), 31-39
**[[Diagnostic_Kits/The licensing of DNA patents by US academic institutions|Highlights]]


= IP Profile of Associations in Kits =
= IP Profile of Associations in Kits =
*Biotechnology Industry Organization (BIO), Available at: http://www.bio.org/ [last accessed April, 17, 2010] (the world's largest biotechnology organization).
*Personalized Medicine Coalition, Available at: http://www.personalizedmedicinecoalition.org/ [last accessed April, 17, 2010].


= Commons based cases in Kits =
= Commons based cases in Kits =
*BioBricks Foundation Available at: http://openwetware.org/wiki/The_BioBricks_Foundation:Legal [last accessed April, 17, 2010].
*Biomarkers Consortium, Available at: http://www.biomarkersconsortium.org/ [last accessed April, 17, 2010].
*Dequeker, Elisabeth et. al., ''Quality control in molecular genetic testing'', Nature Reviews Genetics 2, 717–723 (1 September 2001).
*DNA Patent Database, Available at: http://dnapatents.georgetown.edu/ [last accessed April, 17, 2010].
*Genetic Testing Reference Materials Coordination Program (GeT-RM), Available at: http://wwwn.cdc.gov/dls/genetics/rmmaterials/default.aspx [last accessed April, 17, 2010].
*Kalman, Lisa et. al., ''Development and Characterization of Reference Materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 Genetic Testing'', Journal of Molecular Diagnostics 2009, Vol. 11, No. 6
*Kling. ''Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine?'' EMBO reports (2007) vol. 8 (10) pp. 903-6. Accessed December 14, 2009 at http://www.nature.com/embor/journal/v8/n10/full/7401080.html
**[[Diagnostic Kits/Diagnosis or drug- Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine|Highlights]]
*National Cancer Institute, ''NCI's Clinical Trials Cooperative Group Program''. Available at: http://www.cancer.gov/cancertopics/factsheet/NCI/clinical-trials-cooperative-group [last accessed April, 17, 2010].
*National Institutes of Health, Translating Scientific Discoveries Into Medical Practice , http://www.niaid.nih.gov/labsandresources/techdev/Pages/default.aspx [last accessed April, 17, 2010].
*National Institutes of Health, Uniform Biological Material Transfer Agreement, Available at: http://www.niaid.nih.gov/labsandresources/techdev/Pages/default.aspx [last accessed April, 17, 2010].
*Open Educational Resources for Cancer, Available at: http://oerc.merlot.org/index.html [last accessed April, 17, 2010].
*Registry of Standard Biological Parts, Available at: http://partsregistry.org/Main_Page [last accessed April, 17, 2010].
*SNPedia, Available at: http://www.snpedia.com/index.php/SNPedia [last accessed April, 17, 2010] (SNPedia is a wiki investigating human genetics).
*Trait-o-matic, Available at: http://snp.med.harvard.edu/ [last accessed April, 17, 2010].
*Pratt, Victoria. Development of Genomic Reference Materials for Cystic Fibrosis Genetic Testing, Journal of Molecular Diagnostics 2009, Vol. 11, No. 3
*Promethease, Available at: http://www.snpedia.com/index.php/Promethease [last accessed April, 17, 2010].
*Wilson, Jean Amos., Consensus Characterization of 16 FMR1 Reference Materials: A Consortium Study, Available at: http://jmd.amjpathol.org/cgi/content/abstract/jmoldx.2008.070105v1 [last accessed April, 17, 2010].


= Peer-Production Business models in Kits =
= Peer-Production Business models in Kits =
*CHDWiki: Congenital Heart Defects, Available at: http://homes.esat.kuleuven.be/~bioiuser/chdwiki/index.php/Main_Page [last accessed April, 17, 2010]


= Open Business models in Kits =
= Open Business models in Kits =
*add entries here
[[Category:Diagnostic Kits]]

Latest revision as of 18:04, 17 April 2010

Bibliographic entries used in each research question (1-12; defined by the Field Research Methodology).

Overview of Economics of Intellectual Property in Kits

  • Jensen, K. & Murray, F., 2005. INTELLECTUAL PROPERTY: Enhanced: Intellectual Property Landscape of the Human Genome. Science, 310(5746), 239-240.
  • Mills, A.E. & Tereskerz, P., 2008. DNA-based patents: an empirical analysis. Nat Biotech, 26(9), 993-995.
  • Pressman, L. et al., 2006. The licensing of DNA patents by US academic institutions: an empirical survey. Nat Biotech, 24(1), 31-39

Give an overall picture of the Kits' sector

Outputs and Products of the field: data, narratives and tools produced by the Kits' sector

  • Secretary's Advisory Committee on Genetics, Health, and Society €”Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests - Appendix 1: Compendium of Case Studies on the Impact of Gene Patents and Licensing Practices on Access to Genetic Testing. (2009) Available at: http://oba.od.nih.gov/SACGHS/sacghs_documents.html#GHSDOC_011.

Legal tools available for and in use by the actors of Kits' sector: IP in Kits

  • Holman, Christopher M., The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation. UMKC Law Review, Vol. 76, p. 295, 2007. Available at SSRN: http://ssrn.com/abstract=1090562
  • Microbiological Research Corp. v. Muna, 625 P.2d 690, 700 (Utah 1981)
  • Pressman, L. et al., 2006. The licensing of DNA patents by US academic institutions: an empirical survey. Nat Biotech, 24(1), 31-39

Competitive advantages in Kits

  • Cook-Deegan, R., Chandrasekharan, S. & Angrist, M., 2009. The dangers of diagnostic monopolies. Nature, 458(7237), 405-406.
  • Gibson, Johanna, The Discovery of Invention: Gene Patents and the Question of Patentability (January 01, 2007). Journal of Intellectual Property Rights, Vol. 12, No. 1, 2007. Available at SSRN: http://ssrn.com/abstract=1347087
  • Kane, Eileen, Molecules and Conflict: Cancer, Patents, and Women's Health. American University Journal of Gender, Social Policy & the Law, Vol. 15, No. 2, 2007. Available at SSRN: http://ssrn.com/abstract=960772
  • Ouellette, Lisa Larrimore, Access to Bio-Knowledge: From Gene Patents to Biomedical Materials (June 25, 2009). Stanford Technology Law Review, N1, 2010. Available at SSRN: http://ssrn.com/abstract=1431580
  • Paradise, Jordan K., European Opposition to Exclusive Control Over Predictive Breast Cancer Testing and the Inherent Implications for United States Patent Law and Public Policy: A Case Study of the Myriad Genetics' BRCA Patent Controversy. Food & Drug Law Journal, Vol. 59, No. 1, 2004. Available at SSRN: http://ssrn.com/abstract=897507

IP Profile of Biggest for-profit companies in Kits

  • Pressman, L., Rohrbaugh, M., and Stephen Finley. "Preliminary Findings from a Population Level Study of DNA Patents." SACGHS Public Consultation Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests. (2009) pp. 1-11

IP Profile of non-profit companies in Kits

  • Coriell Personal Medicine Collaborative, Available at: cpmc.coriell.org [last accessed April 17, 2010].
  • Diagnostics for All, Available at: http://www.dfa.org/ [last accessed April 17, 2010] (Whitesides paper microfluidics - based diagnostics; tests non-DNA biomarkers).

IP Profile of Universities working in Kits

  • Pressman, L. et al., 2006. The licensing of DNA patents by US academic institutions: an empirical survey. Nat Biotech, 24(1), 31-39

IP Profile of Associations in Kits

  • Biotechnology Industry Organization (BIO), Available at: http://www.bio.org/ [last accessed April, 17, 2010] (the world's largest biotechnology organization).

Commons based cases in Kits

  • Dequeker, Elisabeth et. al., Quality control in molecular genetic testing, Nature Reviews Genetics 2, 717–723 (1 September 2001).
  • Kalman, Lisa et. al., Development and Characterization of Reference Materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 Genetic Testing, Journal of Molecular Diagnostics 2009, Vol. 11, No. 6
  • Pratt, Victoria. Development of Genomic Reference Materials for Cystic Fibrosis Genetic Testing, Journal of Molecular Diagnostics 2009, Vol. 11, No. 3

Peer-Production Business models in Kits

Open Business models in Kits

  • add entries here